Survival of children with neuroblastoma treated at the Institute of oncology in Ljubljana in two periods
Abstract
Background: Neuroblastoma is a malignant tumor of the sympathetic nervous system, representning about 5 % of all childhood malignancies. The aim of our study was to compare the survival of neuroblastoma patients treated in Slovenia in two time periods, 1994–2007 and 1980–1993, and analyze the influence of different factors on survival. The hypothesis was that there has been an improvement in the survival of neuroblastoma patients treated after 1994.
Methods: Seventy-eight neuroblastoma patients, treated at the Department of Pediatrics and at the Institute of Oncology in Ljubljana in the period 1980–2007 were included in the retrospective study. The list of patients and their basic data were collected from the Cancer Registry of Slovenia. Furtjer data about the patients, tumor characteristics and treatment were collected from patients’ records.
Results: Thirty-nine (50 %) out of seventy-eight neuroblastoma patients included in the study are alive; of the 39 (50 %) dead, 23 (29.5 %) died during primary tumor treatment, 15 (19.2 %) died after recurrent disease, and the cause of death in one (1.3 %) patient remained unknown. The survival rates according to stage of disease, site of primary tumor and tumor size have improved in children treated after 1994, as compared to those treated before 1994. The most important factors influencing the prognosis in both time periods were stage of disease, patients’ age and tumor size at diagnosis while there was no statistical difference in survival according to age at diagnosis and the extent of surgery.
Conclusions: The retrospective study confirmed our hypothesis that the survival of our patients treated after 1994 was better than the survival of those treated before. The most important prognostic factors in both periods were stage of the disease, age at diagnosis and tumor size.
Downloads
References
Zadravec Zaletel L. Preživetje bolnikov z nevroblastomom v različnih časovnih obdobjih [magistrsko delo]. Ljubljana : samozaložba; 1995.
Kumar V, Cotran R, Robbins S. Basic pathology. 7th edition. Philadelphia: Saunders; 2003.
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, et al. International Neuroblastoma Risk Group. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 2009; 27: 365–70.
Pohar Perme M, Jereb B. Trends in survival after childhood cancer in Slovenia between 1957 and 2007. Pediatr Hematol Oncol 2009; 26: 275–286
Normand C, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G. Pharmacol. Genetic alterations in neuroblastoma and their usefulness for clinical management. Bull Cancer 2011; 98: 477–88.
Evans AE, D’Angio GJ, Randolph J. A proposed staging for children with neuroblastoma: children’s cancer study group A. Cancer 1971; 27: 374–8.
Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (The Shimada System). Cancer 1999; 86: 364–72.
Sankila R, Martos Jiménez MC, Miljus D, Pritchard-Jones K, Steliarova-Foucher E, Stiller CA. Geographical comparison of cancer survival in European children (1988–1997): report from the ACCIS project. Eur J Cancer 2006; 42: 1972–80.
Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L, Shuster J, et al. A population-based study of neuroblastoma incidence, survival, and mortality in North America. J Clin Oncol 1992; 2: 323–9.
Cotterill SJ, Pearson ADJ, Pritchard J, Foot ABM, Roald B, Kohler JA, t al. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of the European Neuroblastoma Study Group Survey 1982/1992. Eur J Cancer 2000; 36: 901–8.
Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma: Time trends and regional differences in Europe, 1978–1992. Eur J Cancer 2001; 37: 722–9.
Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System Project. Eur J Cancer 2006; 42: 2081–91.
Schroeder H, Wacher J, Larsson H, Rosthoej S, Rechnitzer C, Petersen BL, et al. Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: A population-based study. Br J Cancer 2009; 100: 853–7.
Conte M, Parodi S, De Bernardi B, Milanaccio C, Mazzocco K, Angelini P, et al. Neuroblastoma in adolescents: The Italian experience. Cancer 2006; 106: 1409–17.
Garaventa A, Boni L, Lo Piccolo MS, Tonini GP, Gambini C, Mancini A, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol 2002; 13: 956–64.
Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, et al. Improved Survival of Children With Neuroblastoma Between 1975 and 2005: A Report of the Italian Neuroblastoma Registry. J Clin Oncol 2010; 28: 2331–8.
Sung KW, Ahn HS, Cho B, Choi YM, Chung NG, Hwang TJ, et al. Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000–2005). J Korean Med Sci 2010; 25: 691–7.
Yalçin B, Kremer LC, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev. 2010; (5):CD006301.
National Cancer Institute: PDQ® Neuroblastoma Treatment. Bethesda, MD: National Cancer Institute Mar 2013. Dosegljivo na: http://cancer.gov/cancertopics/pdq/treatment/neuroblastoma/HealthProfessional.
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007 369: 2106–2120.
Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J 1999 Med 341: 1165–1173.
Saarinen-Pihkala UM, Jahnukainen K, Wikstrom S, et al. Ultrahigh-risk group within the high-risk neuroblastoma category. J pediatr Hematol Oncol. 2013; 35: e254–259
Mugishima H. Current status of molecular biology and treatment strategy for neuroblastoma. Int J Clin Oncol. 2012; 17: 189
Kamijo T, Nakagawara A. Molecular and genetic basis of neuroblastoma. Int J Clin Oncol. 2012; 17: 190–195.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
